^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6007

    i
    Other names: RG6007, RG 6007, RO7283420
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, Wilms tumor 1 inhibitor, HLA-A2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    WP42004: A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=59, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=220 --> 59 | Trial completion date: Feb 2026 --> Aug 2023 | Trial primary completion date: Feb 2026 --> Aug 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    1year
    Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (ASH 2023)
    RO7283420 is the first TCR-L TCB antibody evaluated in AML. We observed pharmacodynamic evidence of T-cell activation and expansion in the clinic, in line with the expected MoA of TCBs, however, at the explored doses, no clear exposure-response relationship and only a modest clinical activity were observed. The safety profile was shown to be consistent with the other TCBs and R/R AML population.
    Clinical • P1 data
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • WT1 (WT1 Transcription Factor)
    |
    HLA-A*02
    |
    RG6007
    over1year
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Recruiting, Hoffmann-La Roche | Suspended --> Recruiting
    Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    over1year
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Suspended, Hoffmann-La Roche | Recruiting --> Suspended
    Trial suspension
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    2years
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> Feb 2026 | Trial primary completion date: Oct 2024 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    2years
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Recruiting, Hoffmann-La Roche | N=160 --> 220
    Enrollment change
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection